THE Overall Objective of This Contract IS to Advance the Development of Monovalent Vaccines for Prevention of Marburg Virus (marv) and Sudan Ebolavirus (sudv) Disease. These Vaccines ARE Based on Recombinant Expression of Filovirus Glycoproteins in
Contract Overview
Contract Amount: $95,592,504 ($95.6M)
Contractor: International Aids Vaccine Initiative Inc.
Awarding Agency: Department of Health and Human Services
Start Date: 2021-09-30
End Date: 2027-11-30
Contract Duration: 2,252 days
Daily Burn Rate: $42.4K/day
Official Description: THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. THESE VACCINES ARE BASED ON RECOMBINANT EXPRESSION OF FILOVIRUS GLYCOPROTEINS IN
Place of Performance
Location: New York, 10004
State: New York Government Spending